Dyadic International, Inc. Announces Research and Development Collaboration with the Israel Institute for Biological Researc...
January 16 2018 - 8:30AM
JUPITER, Fla., Jan. 16, 2018 (GLOBE NEWSWIRE) --
Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global
biotechnology company focused on further improving and applying its
proprietary C1 gene expression platform to speed up the development
and production of biologic vaccines and drugs at flexible
commercial scales, today announced that it has entered into a
research and development collaboration with the Israel Institute
for Biological Research (“IIBR”) to further advance its C1
expression platform for the development and manufacture of
recombinant vaccines and neutralizing agents comprising targeted
antigens and monoclonal antibodies, to combat emerging diseases and
threats.
IIBR is a governmental, applied research
institute specializing in the fields of biology, medicinal
chemistry and environmental sciences. Backed by six decades of
experience, IIBR combines highly trained personnel with
cutting-edge technologies and infra-structure to conduct applied
research and development in the fields of biology, medicinal
chemistry and environmental sciences, in addition to basic research
studies closely related to IIBR's applied projects.
http://www.iibr.gov.il/Default.aspx
“We are delighted that IIBR has selected our C1
technology for their project designed to potentially combat against
emerging diseases and biological threats by deploying the C1 gene
expression platform as a potential game changing technology in
Israel. The objective of the program is to enable the production of
recombinant vaccines and neutralizing agents comprising targeted
antigens and monoclonal antibodies, and in high volumes and low
cost,” said Mark A. Emalfarb, Founder and CEO of Dyadic. “This
project will provide Dyadic with a unique opportunity to work with
such a renowned organization to integrate our C1 gene expression
platform into an end to end product development and manufacturing
capability to produce biologics and take one or more of them
through the regulatory process. Substantially, the work will
be performed at IIBR’s laboratories by using in-house
resources.”
“The IIBR development program will encompass the
spectrum of product and process development utilizing C1’s advanced
genetic techniques and novel characteristics for the production of
recombinant vaccines and neutralizing agents comprising targeted
antigens and monoclonal antibodies. This is a great opportunity for
Dyadic to demonstrate the unique benefits of using the C1
platform,” said Ronen Tchelet, PhD, Dyadic’s VP of Research and
Business Development. “We anticipate that this program, using our
C1 technology, will help bring biologic products to market faster,
and most importantly, create a platform that may help save
lives.”
About Dyadic International,
Inc.
Dyadic International, Inc. is a global
biotechnology company which is developing what it believes will be
a potentially significant biopharmaceutical gene expression
platform based on the fungus Myceliophthora thermophila,
nicknamed C1. The C1 microorganism, which enables the development
and large scale manufacture of low cost proteins, has the potential
to be further developed into a safe and efficient expression system
that may help speed up the development, lower production costs and
improve the performance of biologic vaccines and drugs at flexible
commercial scales. Dyadic is using the C1 technology and
other technologies to conduct research, development and commercial
activities for the development and manufacturing of human and
animal vaccines, monoclonal antibodies, biosimilars and/or
biobetters, and other therapeutic proteins. Dyadic pursues research
and development collaborations, licensing arrangements and other
commercial opportunities with its partners and collaborators to
leverage the value and benefits of using these technologies in the
development and manufacture of biopharmaceuticals. In particular,
as the aging population grows in developed and undeveloped
countries, Dyadic believes the C1 technology may help bring
biologic drugs to market faster, in greater volumes, at lower cost,
and with new properties to drug developers and manufacturers and,
hopefully, improve access and cost to patients and the healthcare
system, but most importantly save lives.
Please visit Dyadic’s website at www.dyadic.com
for additional information, including details regarding Dyadic’s
plans for its biopharmaceutical business.
Dyadic trades on the OTCQX tier of the OTC
marketplace. Investors can find real-time quotes, market
information and financial reports for Dyadic in the Company’s
annual and quarterly reports which are filed with the OTC markets.
Please visit the OTC markets website at
www.otcmarkets.com/stock/DYAI/quote.
Safe Harbor Regarding Forward-Looking
Statements
Certain statements contained in this press
release are forward-looking statements within the meaning of the
federal securities laws. These forward-looking statements involve
risks, uncertainties and other factors that could cause Dyadic’s
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Investors
are urged to consider these factors carefully in evaluating the
forward-looking statements and are cautioned not to place undue
reliance on such forward-looking statements. Any forward-looking
statements speak only as of the date of this press release and,
except as required by law, Dyadic expressly disclaims any intent or
obligation to update or revise any forward-looking statements to
reflect actual results, any changes in expectations or any change
in events. Factors that could cause results to differ materially
include, but are not limited to: (1) general economic, political
and market conditions; (2) our ability to carry out and implement
our biopharmaceutical research and business plans and strategic
initiatives; (3) Dyadic’s ability to retain and attract employees,
consultants, directors and advisors; (4) our ability to implement
and successfully carry out Dyadic’s and third parties research and
development efforts; (5) our ability to obtain new license and
research agreements; (6) our ability to maintain our existing
access to, and/or expand access to third party contract research
organizations in order to carry out our research projects for
ourselves and third parties; (7) competitive pressures and reliance
on key third-party and related party research organizations,
customers and collaborators; and (8) other factors discussed in
Dyadic’s publicly available filings, including information set
forth under the caption “Risk Factors” in our December 31, 2016,
Annual Report filed with OTC Markets on March 24, 2017. New risks
and uncertainties arise from time to time, and it is impossible for
us to predict these events or how they may affect us.
Contact:
Dyadic International, Inc.
Thomas L. Dubinski
Chief Financial Officer
Phone: 561-743-8333
Email: tdubinski@dyadic.com
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Sep 2023 to Sep 2024